Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy | Synapse
April 10, 2026Open Access
Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy
Key Points
To evaluate the impact of early PCSK9 inhibitor use on patient outcomes following endovascular therapy for acute stroke.
Evaluated patients with acute large vessel occlusion receiving endovascular therapy.
Assessed the correlation between PCSK9 inhibitor use and outcomes at 90 days.
Monitored for adverse events during the treatment.
Reduced early adverse reactions (EAR) associated with PCSK9 inhibitor use.
Improved 90-day outcomes noted for patients treated early with PCSK9 inhibitors.
No additional adverse events linked to the use of PCSK9 inhibitors.
Abstract
Early PCSK9 inhibitor use after EVT in patients with acute large vessel occlusion was linked to reduced EAR and better 90-day outcomes without added adverse events.